BCTXBriacell Therapeutics
About Briacell Therapeutics
BriaCell Therapeutics (NASDAQ:BCTX) focuses on the development of targeted and effective immunotherapies for cancer. The cornerstone of their operations is their novel cancer vaccine technology, which aims to harness the patient's immune system to combat cancer cells specifically and effectively. BriaCell's leading project, a clinical stage breast cancer treatment, showcases their commitment to advancing cancer therapy through innovative research and development. Their objective is to transform cancer treatment by developing therapies that are not only potent but also less toxic and more tolerable for patients, aiming to improve quality of life alongside extending survival rates.
What is BCTX known for?
Snapshot
Public US
Ownership
2006
Year founded
16
Employees
West Vancouver, Canada
Head office
1 of 1
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
Canada
Products and/or services of Briacell Therapeutics
- Bria-IMT™, a novel immunotherapy for advanced breast cancer aiming to stimulate the immune system to attack tumor cells.
- Bria-OTS™, an off-the-shelf personalized immunotherapy designed for a wide patient population with minimum manufacturing time.
- BriaDX™, a diagnostic test to predict patient compatibility with their immunotherapies, enhancing treatment precision and effectiveness.
- BriaCell's clinical trial collaboration with Incyte Corporation, exploring novel combination treatments to further improve patient outcomes in advanced breast cancer.
- Development of next-generation cancer vaccines focusing on lung, prostate, and melanoma, intended to provide targeted, effective treatment options.
- Research into immune system modulators to enhance the efficacy of their cancer immunotherapies, aiming to improve survival rates and quality of life for patients.
Briacell Therapeutics executive team
- Dr. William V. Williams FCPA, M.D.CEO, President & Director
- Mr. Gadi Levin B.Com., C.A., CPA, M.B.A.CFO & Corporate Secretary
- Dr. Miguel A. Lopez-Lago Ph.D.Chief Scientific Officer
- Dr. Giuseppe Del Priore M.D., M.P.H.Chief Medical Officer
- Dr. Charles Louis Wiseman FACP, M.D.Founder, Principal Research Advisor & Member of Scientific Advisory Board